Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab

BACKGROUND: Although the standard therapy for advanced-stage hepatocellular carcinoma (HCC) is systemic chemotherapy, the combination of atezolizumab and bevacizumab (atezo + bev) with a high objective response rate may lead to conversion to resection in patients with initially unresectable HCC. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuno, Masayuki, Ishii, Takamichi, Ichida, Akihiko, Soyama, Akihiko, Takemura, Nobuyuki, Hirono, Seiko, Eguchi, Susumu, Hasegawa, Kiyoshi, Sasaki, Yasuharu, Uemura, Kohei, Kokudo, Norihiro, Hatano, Etsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440857/
https://www.ncbi.nlm.nih.gov/pubmed/37605169
http://dx.doi.org/10.1186/s12885-023-11302-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440857/
https://www.ncbi.nlm.nih.gov/pubmed/37605169
http://dx.doi.org/10.1186/s12885-023-11302-6

Ejemplares similares